Mgr. Barbora Říhová, Ph.D.

2021

• Health Technology Assessment of the medical devices: a case study from the Czech Republic

  ROZMARINOVÁ Jana ŘÍHOVÁ Barbora

  Article in Periodical

  NISPAcee Journal of Public Administration and Policy : the Network of Institutes and Schools of Public Administration in Central and Eastern Europe, year: 2021, volume: 14, edition: 2, DOI

2020

• The Outcomes-based Risk Sharing Model for Targeted Drugs Based on the Czech National Register of Reimbursed Health Services

  ŘÍHOVÁ Barbora BENEŠOVÁ Klára JARKOVSKÝ Jiří DEMLOVÁ Regina

  Conference abstract

  Year: 2020, type: Conference abstract

• THE REAL-WORLD COST AND EFFECTIVENESS STUDY OF TREATING mCRC WITH BEVACIZUMAB FOLLOWED BY CETUXIMAB OR PANITUMUMAB IN WT KRAS PATIENTS

  SEHNALOVÁ Irena ŘÍHOVÁ Barbora NĚMEČEK Radim KINTROVÁ Kateřina DEMLOVÁ Regina

  Article in Periodical

  FARMACIA, year: 2020, volume: 68, edition: 3, DOI

2019

• Ekonomický pohled na léčbu bevacizumabem u metastatického kolorektálního karcinomu

  SEHNALOVÁ Irena ŘÍHOVÁ Barbora DEMLOVÁ Regina

  Article in Periodical

  Česká a slovenská farmacie, year: 2019, volume: 68, edition: 2

• Farmakoekonomické hodnocení cetuximabu a panitumumabu v 1. linii léčby mCRC v reálné klinické praxi ČR

  SEHNALOVÁ Irena ŘÍHOVÁ Barbora NĚMEČEK Radim KINTROVÁ Kateřina DEMLOVÁ Regina

  Article in Periodical

  Klinická onkologie, year: 2019, volume: 32, edition: 4, DOI

• The model of outcomes-based risk-sharing agreements applied to targeted drugs in oncology

  ŘÍHOVÁ Barbora DEMLOVÁ Regina

  Conference abstract

  Year: 2019, type: Conference abstract

• The Real-World Cost Study of Treating mCRC with Bevacizumab Followed by EGFRi in WT KRAS patients

  SEHNALOVÁ Irena ŘÍHOVÁ Barbora DEMLOVÁ Regina

  Conference abstract

  Year: 2019, type: Conference abstract

2018

• THE REAL-WORLD COST AND EFFECTIVENESS OF EVEROLIMUS IN METASTATIC BREAST CANCER IN THE CZECH REPUBLIC

  ŘÍHOVÁ Barbora ČERNÁ Radka DEMLOVÁ Regina

  Conference abstract

  Year: 2018, type: Conference abstract

2017

• ANALÝZA NÁKLADŮ NA LÉČBU CETUXIMABEM A PANITUMUMABEM V 1. LINII LÉČBY MCRC

  HRADECKÁ Irena ŘÍHOVÁ Barbora DEMLOVÁ Regina

  Conference abstract

  Year: 2017, type: Conference abstract

• The Cost Study of Cetuximab and Panitumumab in The First-Line Treatment of Mcrc in The Czech Republic

  HRADECKÁ Irena ŘÍHOVÁ Barbora DEMLOVÁ Regina

  Conference abstract

  Year: 2017, type: Conference abstract